KT&G Expands Factory in Turkey to Meet Global Demand.

Jan.21.2025
KT&G Expands Factory in Turkey to Meet Global Demand.
KT&G announced factory expansion in Turkey with new production equipment to meet global demand, aiming to become a top global brand.

According to a report by N.News on October 20th, South Korean tobacco company KT&G announced a factory expansion ceremony held in Turkey.


The ceremony took place at the existing factory in the Tire district of Izmir province, Turkey. KT&G CEO Bang Kyung-Man and South Korean Ambassador to Turkey Jung Yeon-doo attended the event.


With this expansion, the total area of KT&G's Turkish factory has reached 25,000 square meters, increasing by approximately 1.5 times. In addition, two new production equipment have been introduced, bringing the total number of cigarette production lines in the factory to four, with an annual production capacity of 12 billion units.


A spokesperson for KT&G stated that the Turkish factory will serve as the company's export outpost and core production base to meet the growing demand in North Africa and Central and South America markets.


In 2008, KT&G established a factory in Turkey as its first overseas production base. Currently, KT&G is constructing another new factory in Indonesia, and is also planning to complete the construction of a new factory in Kazakhstan by 2025.


Bang Kyung-Man emphasized that the Turkish factory will become an overseas production hub driving global business expansion, as well as an important outpost for KT&G to achieve its vision of becoming a global leader.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

NJOY and Altria ask federal court to halt ITC proceeding, alleging multiple constitutional defects
NJOY and Altria ask federal court to halt ITC proceeding, alleging multiple constitutional defects
A filing in the U.S. District Court for the Eastern District of Virginia (Richmond Division) shows NJOY and Altria entities submitted a plaintiffs’ reply supporting their motion for summary judgment, arguing the challenged ITC proceeding is unconstitutional on multiple grounds, including ALJ appointment authority, removal protections, and Article III limits under the Jarkesy framework. The plaintiffs seek summary judgment and a permanent injunction barring continuation of the ITC proceeding.
Jan.08 by 2FIRSTS.ai
BAT Expects Around 2% Revenue and Operating Profit Growth in FY25
BAT Expects Around 2% Revenue and Operating Profit Growth in FY25
British American Tobacco (BAT) reaffirmed its 2026 guidance while announcing a £1.3 billion (approximately USD 1.65 billion) share buyback for FY26. The company expects around 2% growth in revenue and adjusted profit from operations for FY25. Accelerating New Category growth, driven by Velo Plus and improving U.S. Vuse performance, is expected to deliver double-digit H2 revenue growth.
Dec.09 by 2FIRSTS.ai
Altria CEO Billy Gifford to Retire; Sal Mancuso Named Successor
Altria CEO Billy Gifford to Retire; Sal Mancuso Named Successor
Altria Group, Inc. (NYSE: MO) announced that CEO Billy Gifford will retire at the conclusion of the 2026 Annual Meeting of Shareholders on May 14, 2026, after more than 30 years with the company. The Board of Directors has elected Salvatore (Sal) Mancuso, Altria’s current Executive Vice President and CFO, to succeed him as CEO.
Dec.12 by 2FIRSTS.ai
Poll Shows Britons Favor Regulation Over Bans on Nicotine Pouches
Poll Shows Britons Favor Regulation Over Bans on Nicotine Pouches
A new poll commissioned by We Vape UK reveals that most Britons favor regulation — not prohibition — of nicotine pouches. The survey shows broad public support for harm-reduction policies and frustration with weak government regulation, contrasting sharply with Ireland’s recent decision to ban disposable vapes and impose strict limits on nicotine products.
Nov.25 by 2FIRSTS.ai
ZYN Nicotine Pouches Seek MRTP Authorization; FDA Sets January Meeting
ZYN Nicotine Pouches Seek MRTP Authorization; FDA Sets January Meeting
The U.S. FDA has scheduled a Tobacco Products Scientific Advisory Committee (TPSAC) meeting for January 22, 2026, to review Swedish Match USA’s Modified Risk Tobacco Product (MRTP) applications for 20 ZYN nicotine pouch products. Although the products gained PMTA authorization in early 2025, MRTP approval is required for marketing them with reduced-risk claims.
Nov.24 by 2FIRSTS.ai
Vape Company Takes FDA to Court for Stalling Premarket Decision for Half a Decade
Vape Company Takes FDA to Court for Stalling Premarket Decision for Half a Decade
California-based vape manufacturer Schwartz E-Liquid (USA Vape Lab) has sued the U.S. Food and Drug Administration (FDA) in federal court, alleging the agency unlawfully failed to issue a decision on its premarket application for flavored e-cigarette products for more than five years. The company is seeking a court order compelling the FDA to act within 90 days.
Nov.26 by 2FIRSTS.ai